Famitinib
Poor Performance Status
Guangzhou Institute of Respiratory DiseaseSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Poor Performance Status cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan University of California, Davis | Phase 1/2 | CCC |
Same molecule, other indications
Famitinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →